Numares

Numares AG, a diagnostics company headquartered in Regensburg, Germany, was established in 2004 as a spin-off from Regensburg University. The firm operates on the intersection of metabolomics and artificial intelligence, developing diagnostic tests that analyze patterns of biomarkers, known as metabolite constellations, from a single blood or urine sample. This approach targets complex diseases such as cardiovascular, kidney, liver, and neurological conditions, where single biomarkers may provide insufficient information.

The company's business model involves the development and commercialization of these advanced diagnostic tests, which are run on its proprietary, automated in-vitro diagnostics platform, the AXINON® System. Numares licenses its FDA-cleared AXINON® platform and underlying technologies to clinical laboratories, sharing in the revenue generated from the tests. This strategy aims to make sophisticated metabolic testing more accessible for routine clinical use. Key collaborations include partnerships with Mayo Clinic Laboratories and the analytical instrumentation provider Bruker.

The core of Numares' offering is the AXINON® System, a modular, software-based platform that combines nuclear magnetic resonance (NMR) spectroscopy with machine learning algorithms. A key enabling technology is the company's proprietary Magnetic Group Signaling® (MGS®), which standardizes the NMR signals, allowing for highly reproducible and rapid, high-throughput analysis. In July 2023, the company achieved a significant milestone with the FDA clearance of both the AXINON® System and its first test, the AXINON® LDL-p Test System, for assessing cardiovascular disease risk. This clearance establishes a pathway for future tests currently in development, such as a novel test for kidney function.

Since its founding, Numares has secured significant funding to support its research, development, and commercialization efforts. It has raised capital through multiple rounds from investors including Bayern Kapital, KfW, SHS Capital, and a significant quasi-equity financing of up to €20 million from the European Investment Bank in 2022. The company is led by an executive board that includes Dr. Claus Botzler, Florian Voß, and Andreas Wolf, and a supervisory board chaired by the former CEO, Volker Pfahlert. Keywords: metabolic diagnostics, NMR spectroscopy, machine learning diagnostics, biomarker constellations, AXINON System, metabolomics, in-vitro diagnostics, cardiovascular risk assessment, kidney disease testing, liver disease diagnostics, Magnetic Group Signaling, lipoprotein profiling, diagnostic algorithms, precision medicine, multi-marker testing, clinical laboratory solutions, Regensburg University spin-off, automated diagnostics, metabolite analysis, FDA-cleared NMR test